Evaluation of First-void Urine as an Alternative to Cervical Sampling for Human Papillomavirus (HPV) Testing in Cervical Cancer Screening (Single-center Study).

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT ETIENNE · Feb 9, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to test for the Human Papillomavirus (HPV), which is linked to almost all cases of cervical cancer. The study is exploring whether using a sample of first-void urine (the first urine you pass in the morning) could be a comfortable and effective alternative to the traditional cervical sampling method. This is important because many women find cervical sampling uncomfortable, and this can prevent them from getting regular screenings. Researchers will standardize how the urine is collected to ensure accurate results and will also gather feedback on how easy the urine collection process is for participants.

To be eligible for this study, women aged 30 to 65 who are visiting the Gynecology-Obstetrics department for cervical cancer screening can participate, as long as they have health insurance and have been informed about the study. If you join, you'll be asked to provide a urine sample and complete a questionnaire about your experience. This trial aims to make cervical cancer screening more accessible and comfortable for women, ultimately helping to reduce the number of cervical cancer cases and deaths.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female
• • Age between 30 and 65
• • Consulting in the Gynecology-Obstetrics department for primary cervical cancer screening
• • Patient affiliated or entitled to a social security regimen
• • Patient who has received information about the study and expressed non-opposition
• Exclusion Criteria:
• • -